Abstract

The objective of the Core B facility is to provide expertise and a state of the art facility for large scale, high-resolution genetic mapping, DNA sequencing and state of the art proteomics. The core facility will provide HLA-DQ and HLA-DR typing for all the projects in the program and will perform high throughput SNP genotyping on type 1 diabetes candidate loci other than HLA genes (project 4). Suggestive results will be typed in other projects for confirmation. We will also provide sequencing services for the characterization of GAD65 monoclonal antibodies (project 2) and proteomics analysis for the identification of antigenic proteins in type 1 and type 1.5 diabetes (project 3). These high throughput technologies will aid the program project investigators to determine the genetic, environmental and immunological features which can help predict and cure type 1 diabetes.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Program Projects (P01)
Project #
5P01DK053004-08
Application #
7468456
Study Section
Special Emphasis Panel (ZDK1)
Project Start
2007-07-01
Project End
2008-06-30
Budget Start
2007-07-01
Budget End
2008-06-30
Support Year
8
Fiscal Year
2007
Total Cost
$101,472
Indirect Cost

  Institution

Name
University of Washington
Department
Type
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195

  Publications

Zhao, Lue Ping; Bolouri, Hamid; Zhao, Michael et al. (2016) An Object-Oriented Regression for Building Disease Predictive Models with Multiallelic HLA Genes. Genet Epidemiol 40:315-32
Hao, Wei; Greenbaum, Carla J; Krischer, Jeffrey P et al. (2015) The Effect of DPT-1 Intravenous Insulin Infusion and Daily Subcutaneous Insulin on Endogenous Insulin Secretion and Postprandial Glucose Tolerance. Diabetes Care 38:891-6
Brooks-Worrell, Barbara M; Boyko, Edward J; Palmer, Jerry P (2014) Impact of islet autoimmunity on the progressive ?-cell functional decline in type 2 diabetes. Diabetes Care 37:3286-93
Eringsmark Regnéll, S; Lernmark, A (2013) The environment and the origins of islet autoimmunity and Type 1 diabetes. Diabet Med 30:155-60
Brooks-Worrell, B M; Palmer, J P (2013) Attenuation of islet-specific T cell responses is associated with C-peptide improvement in autoimmune type 2 diabetes patients. Clin Exp Immunol 171:164-70
Skoglund, Camilla; Chéramy, Mikael; Casas, Rosaura et al. (2012) GAD autoantibody epitope pattern after GAD-alum treatment in children and adolescents with type 1 diabetes. Pediatr Diabetes 13:244-50
Nepom, Gerald T (2012) MHC class II tetramers. J Immunol 188:2477-82
Oak, S; Radtke, J; Torn, C et al. (2011) Immunoglobulin subclass profiles of anti-idiotypic antibodies to GAD65Ab differ between type 1 diabetes patients and healthy individuals. Scand J Immunol 74:363-7
Brooks-Worrell, Barbara M; Reichow, Jessica L; Goel, Amit et al. (2011) Identification of autoantibody-negative autoimmune type 2 diabetic patients. Diabetes Care 34:168-73
Vaziri-Sani, Fariba; Oak, Shilpa; Radtke, Jared et al. (2010) ZnT8 autoantibody titers in type 1 diabetes patients decline rapidly after clinical onset. Autoimmunity 43:598-606

Showing the most recent 10 out of 86 publications